Drug Profile
Research programme: anticancer therapeutics - Elstar Therapeutics
Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Elstar Therapeutics
- Class Antibodies; Antineoplastics; Bispecific antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for research development in Haematological-malignancies in USA (Parenteral)
- 28 Jan 2022 No recent reports of development identified for research development in Solid-tumours in USA (Parenteral)
- 01 Dec 2017 Early research in Haematological malignancies in USA (Parenteral)